AstraZeneca and
Merck announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious
BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
